Your browser doesn't support javascript.
loading
Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas.
Sengar, Manju; Jain, Hasmukh; Shet, Tanuja; Sridhar, Epari; Gota, Vikram; Rangarajan, Venkatesh; Laskar, Siddhartha S; Alahari, Aruna; Thorat, Jayashree; Agarwal, Archi; Sharma, Neha; Gupta, Himanshi; Kannan, Sadhana; Kumar, Shikhar; Nayak, Lingaraj; Menon, Hari; Gujral, Sumeet; Bagal, Bhausaheb.
Afiliación
  • Sengar M; Department of Medical Oncology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Jain H; Department of Medical Oncology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Shet T; Department of Pathology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Sridhar E; Department of Pathology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Gota V; Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Rangarajan V; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Laskar SS; Department of Radiation Oncology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Alahari A; Department of General Medicine, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Thorat J; Department of Medical Oncology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Agarwal A; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Sharma N; Department of Medical Oncology, Tata Memorial Centre, Mumbai, India.
  • Gupta H; Hematology Cancer Consortium, Mumbai, India.
  • Kannan S; Department of Biostatistics, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Kumar S; Adult Hematolymphoid Unit, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Nayak L; Adult Hematolymphoid Unit, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Menon H; Department of Haematology & Medical Oncology, St. Johns National Academy of Health Sciences, Bengaluru, India.
  • Gujral S; Department of Pathology, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
  • Bagal B; Adult Hematolymphoid Unit, Tata Memorial Centre, A CI of Homi Bhabha National Institute, Mumbai, India.
Br J Haematol ; 200(4): 429-439, 2023 02.
Article en En | MEDLINE | ID: mdl-36323643
Management of acquired immunodeficiency syndrome (AIDS)-related diffuse large B-cell (DLBCL) and plasmablastic lymphomas (PBL) poses significant challenges. The evidence supports use of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) with or without rituximab as first-line therapy. The need for central venous access, growth factors and significant toxicities limits its use in resource-constrained settings. To address these challenges, we have developed a novel regimen, CVEP (cyclophosphamide, vinblastine, etoposide, and prednisolone) based on the pharmacodynamic principles of dose-adjusted EPOCH. This single-centre phase II study evaluated the efficacy and safety of CVEP regimen in patients with de novo systemic AIDS-related DLBCL and PBL. The primary objective was complete response (CR) rates as assessed by positron emission tomography-computed tomography. The secondary objectives were incidence of Grade 3/4 toxicities, toxicities requiring hospitalisation, and disease-free survival. From May 2011 to February 2017, 42 patients were enrolled. At the end of therapy the CR rates were 69% (29/42) in the intention-to-treat population and 80.5% (29/36) in evaluable patients. At a median follow-up of 69 months, the 5-year disease-free survival was 65.3%. Out of 217 cycles administered, febrile neutropenia occurred in 19.3% and hospitalisation was required in 18.3% of cycles. There were two treatment-related deaths. The CVEP regimen is an active and safe regimen for AIDS-related DLBCL and PBL.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Síndrome de Inmunodeficiencia Adquirida Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Síndrome de Inmunodeficiencia Adquirida Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Reino Unido